Group 1 - Berry Genomics experienced a 5.25% increase in stock price, reaching 14.24 CNY per share, with a trading volume of 294 million CNY and a turnover rate of 6.48%, resulting in a total market capitalization of 5.034 billion CNY [1] - The company, established on April 14, 1997, specializes in high-throughput sequencing technology-based genetic testing, with revenue composition as follows: reagent sales 45.74%, medical testing services 31.24%, basic research services 18.33%, equipment sales 3.48%, and others 1.20% [1] Group 2 - The top circulating shareholder of Berry Genomics includes a fund from Yongying Fund, with the Medical Device ETF (159883) newly entering the top ten circulating shareholders in Q3, holding 1.5268 million shares, which is 0.46% of the circulating shares, resulting in an estimated floating profit of approximately 1.084 million CNY [2] - The Medical Device ETF (159883) was established on April 22, 2021, with a current scale of 4.73 billion CNY, showing a year-to-date return of 9.53% and a ranking of 3722 out of 4216 in its category, while experiencing a one-year loss of 1.36% and a ranking of 3671 out of 3937, with a cumulative loss of 46.89% since inception [2]